| Segment / region | Type | Fiscal year | Currency | Revenue (millions) | Share of revenue |
|---|---|---|---|---|---|
| UNITED STATES | Region | 2025 | USD | 26,419.0 | 71.9% |
| Non-US | Region | 2025 | USD | 10,332.0 | 28.1% |
| UNITED STATES | Region | 2024 | USD | 23,863.0 | 71.4% |
| Non-US | Region | 2024 | USD | 9,561.0 | 28.6% |
| UNITED STATES | Region | 2023 | USD | 19,806.0 | 70.3% |
| Non-US | Region | 2023 | USD | 8,384.0 | 29.7% |
| UNITED STATES | Region | 2022 | USD | 18,595.0 | 70.6% |
| Non-US | Region | 2022 | USD | 7,728.0 | 29.4% |
| UNITED STATES | Region | 2021 | USD | 18,194.0 | 70.0% |
| Non-US | Region | 2021 | USD | 7,785.0 | 30.0% |
| UNITED STATES | Region | 2020 | USD | 18,496.0 | 72.8% |
| Non-US | Region | 2020 | USD | 6,928.0 | 27.3% |
| Other Products | Product | 2025 | USD | 7,263.0 | 20.6% |
| Prolia | Product | 2025 | USD | 4,414.0 | 12.5% |
| Repatha | Product | 2025 | USD | 3,016.0 | 8.5% |
| Otezla | Product | 2025 | USD | 2,265.0 | 6.4% |
| ENBREL | Product | 2025 | USD | 2,226.0 | 6.3% |
| EVENITY | Product | 2025 | USD | 2,100.0 | 5.9% |
| XGEVA | Product | 2025 | USD | 2,084.0 | 5.9% |
| TEPEZZA | Product | 2025 | USD | 1,903.0 | 5.4% |
| Product and Service, Other | Product | 2025 | USD | 1,603.0 | 4.5% |
| BLINCYTO | Product | 2025 | USD | 1,559.0 | 4.4% |
| Nplate | Product | 2025 | USD | 1,524.0 | 4.3% |
| TEZSPIRE | Product | 2025 | USD | 1,478.0 | 4.2% |
| Aranesp | Product | 2025 | USD | 1,389.0 | 3.9% |
| KRYSTEXXA | Product | 2025 | USD | 1,340.0 | 3.8% |
| Vectibix | Product | 2025 | USD | 1,175.0 | 3.3% |
| Other Products | Product | 2024 | USD | 5,630.0 | 16.8% |
| Prolia | Product | 2024 | USD | 4,374.0 | 13.1% |
| ENBREL | Product | 2024 | USD | 3,316.0 | 9.9% |
| XGEVA | Product | 2024 | USD | 2,225.0 | 6.7% |
| Repatha (evolocumab) | Product | 2024 | USD | 2,222.0 | 6.7% |
| Otezla | Product | 2024 | USD | 2,126.0 | 6.4% |
| TEPEZZA | Product | 2024 | USD | 1,851.0 | 5.5% |
| EVENITY | Product | 2024 | USD | 1,563.0 | 4.7% |
| Kyprolis | Product | 2024 | USD | 1,503.0 | 4.5% |
| Nplate | Product | 2024 | USD | 1,456.0 | 4.4% |
| Product and Service, Other | Product | 2024 | USD | 1,398.0 | 4.2% |
| Aranesp | Product | 2024 | USD | 1,342.0 | 4.0% |
| BLINCYTO | Product | 2024 | USD | 1,216.0 | 3.6% |
| KRYSTEXXA | Product | 2024 | USD | 1,185.0 | 3.6% |
| Vectibix | Product | 2024 | USD | 1,045.0 | 3.1% |
| TEZSPIRE | Product | 2024 | USD | 972.0 | 2.9% |
| Other Products | Product | 2023 | USD | 5,263.0 | 18.7% |
| Prolia | Product | 2023 | USD | 4,048.0 | 14.4% |
| ENBREL | Product | 2023 | USD | 3,697.0 | 13.1% |
| Otezla | Product | 2023 | USD | 2,188.0 | 7.8% |
| XGEVA | Product | 2023 | USD | 2,112.0 | 7.5% |
| Repatha (evolocumab) | Product | 2023 | USD | 1,635.0 | 5.8% |
| Nplate | Product | 2023 | USD | 1,477.0 | 5.2% |
| Kyprolis | Product | 2023 | USD | 1,403.0 | 5.0% |
| Aranesp | Product | 2023 | USD | 1,362.0 | 4.8% |
| Product and Service, Other | Product | 2023 | USD | 1,280.0 | 4.5% |
| Evenity | Product | 2023 | USD | 1,160.0 | 4.1% |
| Vectibix | Product | 2023 | USD | 984.0 | 3.5% |
| BLINCYTO | Product | 2023 | USD | 861.0 | 3.1% |
| TEPEZZA | Product | 2023 | USD | 448.0 | 1.6% |
| KRYSTEXXA | Product | 2023 | USD | 272.0 | 1.0% |
| Other Products | Product | 2022 | USD | 5,570.0 | 21.2% |
| ENBREL | Product | 2022 | USD | 4,117.0 | 15.6% |
| Prolia | Product | 2022 | USD | 3,628.0 | 13.8% |
| Otezla | Product | 2022 | USD | 2,288.0 | 8.7% |
| XGEVA | Product | 2022 | USD | 2,014.0 | 7.7% |
| Product and Service, Other | Product | 2022 | USD | 1,522.0 | 5.8% |
| Aranesp | Product | 2022 | USD | 1,421.0 | 5.4% |
| Nplate | Product | 2022 | USD | 1,307.0 | 5.0% |
| Repatha (evolocumab) | Product | 2022 | USD | 1,296.0 | 4.9% |
| Kyprolis | Product | 2022 | USD | 1,247.0 | 4.7% |
| Neulasta | Product | 2022 | USD | 1,126.0 | 4.3% |
| Evenity | Product | 2022 | USD | 787.0 | 3.0% |
| Other Products | Product | 2021 | USD | 5,851.0 | 22.5% |
| ENBREL | Product | 2021 | USD | 4,465.0 | 17.2% |
| Prolia | Product | 2021 | USD | 3,248.0 | 12.5% |
| Otezla | Product | 2021 | USD | 2,249.0 | 8.7% |
| XGEVA | Product | 2021 | USD | 2,018.0 | 7.8% |
| Neulasta | Product | 2021 | USD | 1,734.0 | 6.7% |
| Product and Service, Other | Product | 2021 | USD | 1,682.0 | 6.5% |
| Aranesp | Product | 2021 | USD | 1,480.0 | 5.7% |
| Repatha (evolocumab) | Product | 2021 | USD | 1,117.0 | 4.3% |
| Kyprolis | Product | 2021 | USD | 1,108.0 | 4.3% |
| Nplate | Product | 2021 | USD | 1,027.0 | 4.0% |
| Other Products | Product | 2020 | USD | 6,574.0 | 25.9% |
| ENBREL | Product | 2020 | USD | 4,996.0 | 19.7% |
| Prolia | Product | 2020 | USD | 2,763.0 | 10.9% |
| Neulasta | Product | 2020 | USD | 2,293.0 | 9.0% |
| Otezla | Product | 2020 | USD | 2,195.0 | 8.6% |
| XGEVA | Product | 2020 | USD | 1,899.0 | 7.5% |
| Aranesp | Product | 2020 | USD | 1,568.0 | 6.2% |
| Product and Service, Other | Product | 2020 | USD | 1,184.0 | 4.7% |
| Kyprolis | Product | 2020 | USD | 1,065.0 | 4.2% |
| Repatha (evolocumab) | Product | 2020 | USD | 887.0 | 3.5% |
Product and geographic breakdowns describe the same revenue from different perspectives and should not be added together.
